Advanced search
Publication Cover
OncoTargets and Therapy Volume 12, 2019 - Issue
Submit an article Journal homepage
108
Views
18
CrossRef citations to date
0
Altmetric
Original Research

Rhein sensitizes human colorectal cancer cells to EGFR inhibitors by inhibiting STAT3 pathway

Yan Zhuang1 The Institute of Life Sciences, Wenzhou University, Wenzhou, Zhejiang 325035, People’s Republic of China;2 School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, People’s Republic of China
,
Ying Bai1 The Institute of Life Sciences, Wenzhou University, Wenzhou, Zhejiang 325035, People’s Republic of China;2 School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, People’s Republic of China
,
Yan Hu3 Department of Pharmacy, Taizhou Enze Medical Center (Group), Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang 317000, People’s Republic of China
,
Yueqin Guo1 The Institute of Life Sciences, Wenzhou University, Wenzhou, Zhejiang 325035, People’s Republic of China;2 School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, People’s Republic of China
,
Lingyuan Xu1 The Institute of Life Sciences, Wenzhou University, Wenzhou, Zhejiang 325035, People’s Republic of China;2 School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, People’s Republic of China
,
Wanle Hu4 Department of Coloproctology, The Second Affiliated Hospital and Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325000, People’s Republic of China
,
Lehe Yang1 The Institute of Life Sciences, Wenzhou University, Wenzhou, Zhejiang 325035, People’s Republic of China;2 School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, People’s Republic of China
,
Chengguang Zhao1 The Institute of Life Sciences, Wenzhou University, Wenzhou, Zhejiang 325035, People’s Republic of China;2 School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, People’s Republic of China
,
Xiaokun Li1 The Institute of Life Sciences, Wenzhou University, Wenzhou, Zhejiang 325035, People’s Republic of China;2 School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, People’s Republic of ChinaCorrespondence[email protected]
&
Haiyang Zhao1 The Institute of Life Sciences, Wenzhou University, Wenzhou, Zhejiang 325035, People’s Republic of China;2 School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 5281-5291 | Published online: 03 Jul 2019

References

  • Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532–536. doi:10.1038/nature1115622722830
  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.30620402
  • Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68:250–281.29846947
  • Okada Y, Kimura T, Nakagawa T, et al. EGFR downregulation after Anti-EGFR therapy predicts the antitumor effect in colorectal cancer. Mol Cancer Re. 2017;15:1445–1454. doi:10.1158/1541-7786.MCR-17-0157
  • Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci. 2015;36:422–439. doi:10.1016/j.tips.2015.04.00525975227
  • Bertotti A, Papp E, Jones S, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature. 2015;526:263–267. doi:10.1038/nature1496926416732
  • Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 2014;4:1269–1280. doi:10.1158/2159-8290.CD-13-064625293556
  • Troiani T, Martinelli E, Napolitano S, et al. Increased TGF-alpha as a mechanism of acquired resistance to the Anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. Clin Cancer Res. 2013;19:6751–6765. doi:10.1158/1078-0432.CCR-13-042324122793
  • Miroddi M, Sterrantino C, Simmonds M, et al. Systematic review and meta-analysis of the risk of severe and life-threatening thromboembolism in cancer patients receiving anti-EGFR monoclonal antibodies (cetuximab or panitumumab). Int J Cancer. 2016;139:2370–2380. doi:10.1002/ijc.v139.1027450994
  • Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. NAt Rev Clin Oncol. 2018;15:234–248. doi:10.1038/nrclinonc.2018.829405201
  • Huynh J, Chand A, Gough D, Ernst M. Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map. Nat Rev Cancer. 2019;19:82–96. doi:10.1038/s41568-018-0090-8.
  • Yang L, Lin S, Kang Y, et al. Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway. J Exp Clin Cancer Res. 2019;38:31. doi:10.1186/s13046-018-1015-930674340
  • Zhao CG, Li HM, Lin HJ, Yang SL, Lin JY, Liang G. Feedback activation of STAT3 as a cancer drug-resistance mechanism. Trends Pharmacol Sci. 2016;37:47–61. doi:10.1016/j.tips.2015.10.00126576830
  • Shi LY, Zheng HL, Hu WL, et al. Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer. Oncotargets Ther. 2017;10:1767–1776. doi:10.2147/OTT.S129449
  • Zhao CG, Xiao H, Wu XJ, et al. Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells. Oncotarget. 2015;6:14472–14487.25961376
  • Beebe JD, Liu JY, Zhang JT. Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we? Pharmacol Ther. 2018;191:74–91. doi:10.1016/j.pharmthera.2018.06.00629933035
  • Zheng H, Yang L, Kang Y, et al. Alantolactone sensitizes human pancreatic cancer cells to EGFR inhibitors through the inhibition of STAT3 signaling. Mol Carcinog. 2019;58:565–576. doi:10.1002/mc.22951.
  • Yang LH, Li JF, Xu LY, et al. Rhein shows potent efficacy against non-small-cell lung cancer through inhibiting the STAT3 pathway. Cancer Manag Res. 2019;11:1167–1176. doi:10.2147/CMAR.S17151730774444
  • Zheng HL, Hong H, Zhang LL, et al. Nifuratel, a novel STAT3 inhibitor with potent activity against human gastric cancer cells. Cancer Manag Res. 2017;9:565–571. doi:10.2147/CMAR.S14617329138596
  • Wei J, Ma L, Lai YH, et al. Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy. J Exp Clin Cancer Res. 2019;38:63. doi:10.1186/s13046-019-1072-830736824
  • Bai EC, Yang LH, Xiang YQ, et al. L61H46 shows potent efficacy against human pancreatic cancer through inhibiting STAT3 pathway. Cancer Manag Res. 2018;10:565–581. doi:10.2147/CMAR.S15909029606890
  • Bin Z, Hong Z, Zheng HL, et al. Pectolinarigenin suppresses pancreatic cancer cell growth by inhibiting STAT3 signaling. Nat Prod Commun. 2017;12:1861–1864.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.